Post-earnings recap
Reported
Tue, May 11, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
13%
Vaxcyte's earnings report showed a loss per share of $0.41, which was in line with expectations, but no revenue figures were disclosed. The stock reacted positively, increasing by 5.41%, likely due to investor optimism about the company's future developments despite the lack of guidance. The management's focus on their pipeline suggests they are prioritizing long-term growth over short-term revenue.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to ongoing development efforts. They did not provide any updates on revenue expectations.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—